You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / AJANTA PHARMA

AJANTA PHARMA
Intrinsic Value | Fundamental Analysis

Returns | 1W : -2.9% , 1M : 14.4%,1Y : 39.3%
BOM : 532331     NSE : AJANTPHARM    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward
Pledged Shares : None or < 25%
May 14,2021
Price(EOD): Rs. 1,959.75
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
MarketCap: Rs. 16,951.84 Cr
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
AJANTA PHARMA -2.9% 14.4% 39.3%
SUN PHARMACEUTICAL INDUSTRIES 1.7% 11.6% 51.5%
DR REDDYS LABORATORIES 0.4% 4.1% 40.6%
DIVIS LABORATORIES -0.2% 6.3% 71.8%
CIPLA 2.4% 0.1% 57.7%
BIOCON 2.1% -3.8% 12.2%
AUROBINDO PHARMA -0.6% 9.9% 47.1%
LUPIN -1.4% 12.7% 42.7%
TORRENT PHARMACEUTICALS 4.1% 6.5% 11.5%


FUNDAMENTAL ANALYSIS OF AJANTA PHARMA

 
Fundamentals Score
[Last Annual Data : Mar2020 | TTM
Trailing Twelve Months (TTM) is calculated using last 4 quarterly data and is a good substitute to track Annual results.
Learn More
]
Show Me the Stocks with Fundamentals better than AJANTA PHARMA Premium


VALUATION OF AJANTA PHARMA

 
Valuation Score
Ratio Consolidated
P/E
P/B
P/S
36.56
P/E Calculated based on EPS of 53.6
[ Mar2020 - Consolidated Results ]

6.58
P/B Calculated based on Book Value of 297.8
[ Mar2020 - Consolidated Results ]

5.87
P/S Calculated based on Revenues of 2889.69 Cr
[ TTM - Consolidated Results ]

Show Me the Stocks with Valuation better than AJANTA PHARMA Premium


FAIR VALUE OF AJANTA PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
32%
0%
12%

SHARE PRICE MOMENTUM OF AJANTA PHARMA

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2020
2019
2018
Avg_3yrs
0
0
0
-
0.02
0.02
0
0.01
[Last Annual Data : Mar2020]

PLEDGED SHARES

Pledged Shares
15.49 %
As on : Mar2021

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
1.08%
7.34%
6.18%
-9.83%
10.98%
71.41%
30.09%
23.3%
QtrlyTrend
6
Latest Qtr: Mar2021

AJANTA PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 0.2% 6.8% 61%
S&P BSE MIDSMALLCAP -0.3% 6.2% 97.6%
S&P BSE 400 MIDSMALLCAP -0.4% 6.1% 98.4%
S&P BSE MID CAP -0.5% 4.3% 81.8%
S&P BSE ALLCAP -0.7% 4% 68.7%
S&P BSE 500 -0.7% 3.8% 67.2%
S&P BSE LARGE MIDCAP -0.7% 3.4% 63%
S&P BSE 200 -0.8% 3.5% 64.2%
S&P BSE 250 LARGEMIDCAP -0.8% 3.5% 64.6%
S&P BSE MOMENTUM -0.9% 4.7% 40.8%
S&P BSE 150 MIDCAP -0.9% 5.1% 90.8%
NSE Indices1W1M1Y
NIFTY MID SMALL400 -0.3% 6.2% 99.8%
NIFTY MIDCAP150 -0.7% 4.9% 90.7%
NIFTY 500 -0.7% 3.7% 66.7%
NIFTY FREE MIDCAP 100 -0.7% 5.4% 94%
NIFTY LARGE MIDCAP 250 -0.8% 4% 74.5%
NIFTY 200 -0.8% 3.4% 63.1%

FAQ [Frequently Asked Questions]


Is AJANTPHARM good for long term investment?

As on 14-May-2021, the Fundamentals of AJANTPHARM are Strong and hence it's good for long term investment! See Financial Performance of AJANTA PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is AJANTPHARM UnderValued or OverValued?

As on 14-May-2021, AJANTPHARM is Fairly Valued and investors can wait for the buying opportunity once it becomes under valued!

What is the Intrinsic Value of AJANTPHARM ?

As on 14-May-2021, the Intrinsic Value of AJANTPHARM is Rs. 1,742.16 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 1,484.29
Fair Value [Median EV / Sales Model] : Rs. 1,951.51
Fair Value [Median Price / Sales Model] : Rs. 1,742.16
Median Fair Value of AJANTPHARM : Rs. 1,742.16

Is AJANTPHARM trading at a Premium or Discount?

As on 14-May-2021, AJANTPHARM is trading at a Premium of 12% based on the Median Intrinsic Value!

Is it right time to buy AJANTPHARM shares?

As on 14-May-2021, AJANTPHARM is Fairly Valued and investors can wait for the buying opportunity once it becomes under valued!

What is the Financial Performance of Industry Peers of AJANTPHARM?

Check out Financials of Industry Peers using below links:
Financials of SUN PHARMACEUTICAL INDUSTRIES LTD
Financials of DR REDDYS LABORATORIES LTD
Financials of DIVIS LABORATORIES LTD
Financials of CIPLA LTD
Financials of BIOCON LTD
Financials of AUROBINDO PHARMA LTD
Financials of LUPIN LTD
Financials of TORRENT PHARMACEUTICALS LTD
Financials of CADILA HEALTHCARE LTD
Financials of ABBOTT INDIA LTD

What are the Frequent Comparisons with AJANTPHARM?

AJANTA PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DR REDDYS LABORATORIES LTD
AJANTA PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD
AJANTA PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD
AJANTA PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs BIOCON LTD
AJANTA PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs AUROBINDO PHARMA LTD
AJANTA PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs LUPIN LTD
AJANTA PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs TORRENT PHARMACEUTICALS LTD
AJANTA PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs CADILA HEALTHCARE LTD
AJANTA PHARMA LTD vs SUN PHARMACEUTICAL INDUSTRIES LTD vs ABBOTT INDIA LTD

Open Demat Account & Start Investing
    Affiliate Links

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z